Compare Extra Space Storage, Inc. (EXR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Extra Space Storage, Inc. trades at $146.41 (market cap $30.98B), while Vertex Pharmaceuticals Incorporated trades at $528.02 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.3× Extra Space Storage, Inc.'s market cap, and Extra Space Storage, Inc. pays a 4.42% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| EXR | VRTX | |
|---|---|---|
Market Cap | $30.98B | $132.79B |
Sector | Real Estate | Health |
52-Week High | $152.85 | $529.65 |
52-Week Low | $126.67 | $376.62 |
Enterprise Value | $44.70B | $126.92B |
Dividend Yield | 4.42% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
